Second and third generic Saxenda products reach US pharmacies

Two more companies began marketing generic versions of Saxenda, the liraglutide injection approved for weight management, in the final days of February 2026. Cipla USA lists a first marketing date of Feb. 25, 2026 under abbreviated new drug application ANDA217234, and Orbicular lists Feb. 26, 2026. Biocon Pharma followed about a month later, on March 27, 2026. The additions end a stretch of roughly six months in which Teva was the only company selling a generic of the weight-management version of liraglutide.

Liraglutide is a GLP-1 receptor agonist, the same drug class as semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) ^[1]. It is an older, once-daily injection rather than a weekly one. Novo Nordisk sells the molecule under two brands: Victoza, approved in 2010 for type 2 diabetes under NDA022341, and Saxenda, approved for weight management under NDA206321 and listed in FDA's directory with a marketing start date of Dec. 31, 2014 ^[1].

What the FDA listings show

FDA's National Drug Code directory is a registry of products companies have told the agency they are selling. It is the clearest public signal that a generic has actually reached distribution, as opposed to simply being approved.

Teva's generic, filed under ANDA214568, carries a marketing start date of Aug. 28, 2025 and is packaged as five prefilled pens per carton at a strength of 6 mg/mL — the same carton configuration and concentration used for Saxenda ^[1]. Teva's listing also carries a marketing end date of Sept. 30, 2027 ^[1]; end dates in this database often reflect listing administration rather than a planned exit, and the database does not explain the reason.

A separate generic from Meitheal Pharmaceuticals, under ANDA218115, has been listed since April 2, 2025 in two- and three-pen cartons ^[1] — the packaging used for Victoza, the diabetes brand. That distinction matters when comparing launch dates: the diabetes-labeled generic arrived first, and the weight-management version followed months later.

As of the most recent data refresh on Sept. 11, 2026, FDA's directory contained 62 listings matching liraglutide, including finished drug products, relabeler listings and bulk active-ingredient entries from suppliers such as Novo Nordisk A/S, Biocon Limited and Polypeptide Laboratories ^[1].

Why it matters for patients

More sellers of the same molecule generally means more competition, but the FDA listing database does not report prices, and none of the sources here include what any of these generics cost at the pharmacy counter or what insurers will pay. That is not yet known from this data.

The practical questions for someone already using liraglutide 3 mg are supply and substitution. Generic products approved through an ANDA are expected to be therapeutically equivalent to the brand, and pharmacies may substitute them depending on state law and the prescription. With four companies now listing the weight-management version — Teva, Cipla, Orbicular and Biocon Pharma — a shortage or backorder at one supplier is less likely to leave a pharmacy with nothing to dispense. The pen device, carton size and labeling can still differ between manufacturers, which is a reason some people notice a change when a pharmacy switches sources.

It is also worth keeping the two liraglutide indications straight. The diabetes-labeled generics reference Victoza; the weight-management generics reference Saxenda. Insurance coverage in the US has historically treated diabetes and obesity drugs very differently, and a generic's availability does not by itself change a plan's coverage rules.

What happens next

The next milestones to watch are pricing disclosures and whether additional ANDA holders add listings. Teva's listed marketing end date of Sept. 30, 2027 is the only forward-looking date in the current records ^[1]. Whether generic liraglutide pulls demand away from newer weekly GLP-1s, or mostly serves people who cannot get those drugs covered, is not addressed in these sources.